Yale School of Public Health Symposium on tissue imaging mass spectrometry: illuminating phenotypic heterogeneity and drug disposition at the molecular level

Affiliations

• ¹ Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, USA.
• ² Biomolecular Mass Spectrometry Imaging, National Resource for Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
• ³ Departments of Biochemistry and the Mass Spectrometry Research Center, Vanderbilt University School of Medicine, Nashville, USA.
• ⁴ Department of Bio-Imaging, Platform Science and Technology, GSK, King of Prussia, USA.
• ⁵ Biodesix Inc., Boulder, USA.
• ⁶ Pathology, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
• ⁷ Departments of Biochemistry and Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, USA.
• ⁸ Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, USA.
• ⁹ Computational and Systems Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
• ¹⁰ Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, USA.
• ¹¹ Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, USA. vasilis.vasiliou@yale.edu.
• ¹² Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, USA. vasilis.vasiliou@yale.edu.
• ¹³ Department of Ophthalmology and Visual Science, Yale School of Medicine, Yale University, New Haven, USA. vasilis.vasiliou@yale.edu.